A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.

Summary

This is a study to investigate the effectiveness and safety of \[S,S\]-Reboxetine in relieving the symptoms of Fibromyalgia in patients. A previous study demonstrated clinically meaningful treatment effects in fibromyalgia, based on pain and functional endpoints.

Timeline

Start

2007-12

Primary completion

2009-05

Completion

2009-05

Outcome

Met primary endpoint

paper Patients receiving all dosages of esreboxetine demonstrated statistically significant improvements in the pain score (P≤0.025), the FIQ score (P≤0.023) PMID 22275142 ↗

release “trial conducted by Pfizer in 1,122 patients with fibromyalgia treated with esreboxetine or placebo for 14 weeks, the study met the two primary endpoints” pfizer.com ↗

Publications

• Arnold LM, Hirsch I, Sanders P, Ellis A, Hughes B. Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen-week, randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum. 2012 Jul;64(7):2387-97. doi: 10.1002/art.34390.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	[S,S]-Reboxetine	Unknown	4 mg	Oral
Subject	[S,S]-Reboxetine	Unknown	8 mg	Oral
Subject	[S,S]-Reboxetine	Unknown	10 mg	Oral

Indications